The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man

Thrombosis Research
J HolstP Ostergaard

Abstract

Heparin, a negatively charged sulphated glycosaminoglycan, is clinically the most important antithrombotic drug. Heparin augments the inhibitory activity of antithrombin (AT) towards thrombin, factor Xa (FXa) and other activated clotting enzymes. Tissue factor pathway inhibitor (TFPI) is an endogenous heparin releasable three domain Kunitz-type coagulation inhibitor which inhibits the crucial tissue factor-factor VIIa (TF-FVIIa) dependent coagulation pathway in the presence of FXa. The importance of the TF-FVIIa pathway and TFPI has recently been reviewed (1). TFPI is located to different vascular pools, the largest being the vascular endothelium from where TFPI can be released dose-dependently to the blood by heparins (2). TFPI is speculated to contribute to the anticoagulant properties of heparins, but to which degree is not yet fully understood. In recent years low molecular weight heparins (LMWH) have proven to be effective and safe both for prophylactic (3) and therapeutic treatment (4) of deep vein thrombosis (DVT). Protamine is the least toxic and clinically most commonly used antidote to heparin. However, in vitro and in vivo LMW heparinized blood is not fully neutralized by protamine, as substantial anti-Xa activity re...Continue Reading

References

Jun 15, 1988·Thrombosis Research·P M SandsetM L Larsen
Oct 1, 1994·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·J HolstP B Ostergaard
Jun 1, 1993·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·C J BrindleyL F Chasseaud
Nov 5, 1997·Thrombosis Research·P B OstergaardJ B Hansen

❮ Previous
Next ❯

Citations

Nov 13, 2001·British Journal of Haematology·A J ChuN Ramos
May 13, 2006·Journal of Thrombosis and Haemostasis : JTH·B S DonahueA E Mast
Jul 10, 2001·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·G CellaJ Fareed
Dec 14, 2006·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Jyothi MaddineniJawed Fareed
May 13, 2010·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Jacqueline KuziejWalter Jeske
Jan 4, 2007·Seminars in Cardiothoracic and Vascular Anesthesia·Steven T MorozowichIan J Welsby
Jun 10, 2000·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·B BendzP M Sandset
Jan 29, 2017·Current Treatment Options in Neurology·Joshua A StoneShadi Yaghi
Sep 28, 2002·Heart Disease·Nina N Wong

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.